MRX on Nasdaq

Medicis Pharmaceutical

Logo: https://www.marketbeat.com/stocks/NYSE/MRX/, Non-free logo, via Wikipedia4

Medical cosmetics company

Medicis Pharmaceutical is a medical cosmetics company based in Bridgewater, New Jersey. It is a subsidiary of Valeant Pharmaceuticals, which acquired the company in 2012.3 From Wikipedia, CC BY-SA 4.0

Price unavailable

Last updated Oct 16, 2026.

Overview

$2.0BRevenue, fiscal 20255
$307.7MNet income, fiscal 20255
1988Founded1

Compare with Tradeweb Llc, BGC Partners or Cboe Global Markets, Inc., or pick any stock.

  • TickerMRX on Nasdaq1
  • Industrypharmaceutical industry1
  • HeadquartersScottsdale1
  • Websitewww.medicis.com
  • Incorporated inBermuda6
  • Business addressCrawford House, 50 Cedar Avenue, Hamilton, Hm116
  • Filer categoryLarge accelerated filer6

Medicis Pharmaceutical is a medical cosmetics company based in Bridgewater, New Jersey. It is a subsidiary of Valeant Pharmaceuticals, which acquired the company in 2012. Medicis is known for products such as Solodyn and Ziana for treating acne, and for Restylane and Dysport for treating facial wrinkles.3

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

15.2%Net margin5
26.9%Revenue growth, 20255
$654.4MFree cash flow5

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Other costs85¢$1.7B
  • Profit15¢$307.7M

Out of $2.0B in revenue.5

Where each dollar of operating cash went, fiscal 2025

  • Capital spending2¢$13.1M
  • Kept or used elsewhere98¢$654.4M

Out of $667.5M of cash from operations.5

Financial statements

Revenue85$2.0B in 2025+185% since 2022
0$1.0B$2.0B$3.0B2022: $711.1M$711.1M20222023: $1.2B$1.2B2023+75%2024: $1.6B$1.6B2024+28%2025: $2.0B$2.0B2025+27%
Net income85$307.7M in 2025+213% since 2022
0$100.0M$200.0M$300.0M$400.0M2022: $98.2M$98.2M20222023: $141.3M$141.3M2023+44%2024: $218.0M$218.0M2024+54%2025: $307.7M$307.7M2025+41%
Fiscal year20212022202320242025
Revenue$711.1M8$1.2B5$1.6B5$2.0B5
Net income$98.2M8$141.3M5$218.0M5$307.7M5
Earnings per share$1.398$1.945$2.965$4.125
Earnings per share (diluted)$1.368$1.825$2.725$3.865

Compare Medicis Pharmaceutical with another company

The story

Founded by Jonah Shacknai in 1988.1

Medicis was founded in Scottsdale, Arizona in 1988 by Jonah Shacknai and John Holaday. The company held its IPO in 1990 and launched its first products over the following year.

1997 Acquisition of GenDerm

In December 1997, Medicis acquired dermatology pharmaceuticals company GenDerm Corporation for $60M in cash. It also acquired Ucyclyd Pharma, a Baltimore-based private company, for $23.4 million in April 1999. Ucyclyd's main product was Buphenyl (sodium phenylbutyrate), used for treating urea cycle disorders. In 2005, they rejected a $2.2 billion unsolicited takeover bid by Mentor.

2011 Sale of LipoSonix to Solta Medical

In September 2011, the company sold its rights to the LipoSonix system to Solta Medical for $35 million. LipoSonix is an ultrasound device intended to help destroy fat deposits in the vicinity of the stomach referred to as "belly fat". For the year, Medicis recorded $721 million in revenue with a gross profit margin of roughly 90 percent.

2011-2018 Media Attention

The company's founder, Jonah Shacknai, came to media attention in 2011 due to investigations into the deaths of his son Max and girlfriend Rebecca Zahau. A jury in a 2018 civil trial concluded that the death of Zahau a homicide by Jonah's brother, Adam Shacknai.

2012 buyout by Valeant

In September 2012, Canadian-based Valeant Pharmaceuticals and Medicis' management agreed that Valeant would acquire the company for $2.6 billion, or $44/share, 39 percent more than the stock’s Aug. 31 closing price. The deal was subject to shareholder and regulatory approvals. It was the 11th acquisition for Valeant that year and was expected to close the next summer. The transaction was completed in December 2012, with Medicis delisting and becoming a subsidiary of Valeant, after which its board of directors disbanded. Later in December, Valeant dismissed 319 of Medicis' employees and retained 117. Shaknai left the company at the time of the acquisition and Medicis’ executive vice president and COO Ryan Weldon became company group chairman.

2015 Arizona Consumer Fraud Lawsuit and Judicial Precedent

In 2015 Medicis was charged under the Arizona Consumer Fraud Act, and Arizona allowed consumer fraud law to apply against pharmaceutical companies for the first time. Medicis marketed an extended release form of minocycline, known to cause a lupus-like autoimmune response.

From Wikipedia’s article on Medicis Pharmaceutical, shared under CC BY-SA 4.0.7

Leadership

Who has led Medicis Pharmaceutical, and when. Pick a name to see everywhere that person has worked.

Subsidiaries and ownership

Parent company

From Wikidata.1

Former names

  • Marex Group plcDec 6, 2023 to Jul 1, 20266

Timeline

  1. 1988Founded Founded1

Recent filings

  1. Oct 14, 20264
  2. Oct 14, 20264
  3. Oct 13, 2026424B2 PRICING SUPPLEMENT
  4. Oct 13, 2026144
  5. Oct 13, 2026424B2 PRICING SUPPLEMENT
  6. Oct 9, 2026424B2 PRICING SUPPLEMENT
  7. Oct 8, 2026424B2 PRICING SUPPLEMENT
  8. Oct 8, 2026424B2 PRICING SUPPLEMENT
  9. Oct 7, 20266-K
  10. Oct 7, 2026424B2 PRICING SUPPLEMENT
  11. Oct 7, 2026424B2 PRICING SUPPLEMENT
  12. Oct 6, 2026424B2 PRICING SUPPLEMENT
  13. Oct 6, 2026424B2 PRICING SUPPLEMENT
  14. Oct 6, 2026424B2 PRICING SUPPLEMENT
  15. Oct 6, 2026N-PX

Every filing from the last three years, summarized. The full record is on SEC EDGAR.2